maleimide derivatives/GSK-3 inhibitors (University of Barcelona/CSIC)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug Namemaleimide derivatives/GSK-3 inhibitors (University of Barcelona/CSIC)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlycogen synthase kinase-3 inhibitors
TargetsGlycogen synthase kinase-3
Therapy Area/IndicationsNerve DegenerationInflammationDiabetes Mellitus, Type 2 +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversitat De Barcelona
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversitat De BarcelonaSpanish National Research Council
Active IndicationsN/A
Inactive IndicationsNerve DegenerationInflammationDiabetes Mellitus, Type 2 +[4] 

Other Information

ATC CodeN/A
Related LinksN/A